Coherus BioSciences, Inc. (CHRS) is a leading biopharmaceutical company specializing in the research, development, and commercialization of biosimilar drugs. A biosimilar, as the name suggests, is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original, innovator products; they can be manufactured when the original product's patent expires.
Incorporated in 2010 and headquartered in Redwood City, California, Coherus BioSciences was founded with the vision of increasing patient access to essential, life-saving drugs. Over the years, Coherus BioSciences has become a renowned name in the industry due to its commitment towards developing biosimilars that are safe, cost-effective, and most importantly, intended to increase patient access to important treatments.
Coherus BioSciences' portfolio includes Udenyca, a biosimilar to Neulasta which is a long-acting granulocyte colony-stimulating factor used to prevent infections in patients undergoing chemotherapy. This product marked Coherus BioSciences' first commercial product launch, after its U.S. FDA approval in 2018.
The company has an active pipeline that focuses on the areas of immunology (anti-TNFs), ophthalmology, and oncology. Their strategy is to specifically pursue biosimilar versions of existing blockbuster drugs, providing them a unique value proposition in the competitive landscape of specialty pharmaceuticals.
Coherus BioSciences, Inc. benefits from a strong management team comprised of industry veterans and experts in the field of biosimilars. The team is dedicated to the mission of improving lives by maintaining exceptional quality standards, scientific expertise, and the capacity to deliver reliable affordable medicines to patients worldwide.
The company's shares are listed on the NASDAQ exchange under the ticker symbol "CHRS". With its unique business approach and commitment to enhancing patient access to necessary treatments, Coherus BioSciences Inc. is a pioneer in the development and commercialization of biosimilars, making it a significant player within the evolving pharmaceutical industry. Coherus’ journey and success so far testifies to the critical role they play in the global healthcare community.
In conclusion, Coherus BioSciences, Inc., through its research, development, and commercialization of biosimilars, strives to reduce healthcare costs, increase patient access, and offer reliable, safe, and effective treatment options for everyone. With patient welfare at their core, the company continues to innovate, challenge, and inspire in its quest to bring essential medicines to all who need them.